Results 181 to 190 of about 4,254,417 (298)

A systematic review and meta-analysis assessing the influence of histone deacetylase 6 inhibition on brain infarction and neurological function following acute ischaemic stroke in rodent models. [PDF]

J Cereb Blood Flow Metab
Ma OB, Noack TC, Trollope AF, Moxon JV.
europepmc   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Inhibition of death receptor signals by cellular FLIP

Nature, 1997
M. Irmler, M. Thome, M. Hahne, P. Schneider, K. Hofmann, Véronique Steiner, J. Bodmer, M. Schröter, K. Burns, C. Mattmann, D. Rimoldi, L. French, J. Tschopp   +12 more
semanticscholar   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Lactate Dehydrogenase Inhibition Reverts the Fatty Acid-Induced Neurotoxic Phenotype of Astrocytes. [PDF]

Glia
Esteve D, Bresque M, Okhuevbie D, Ramachandran S, Pehar M, Vargas MR.   +5 more
europepmc   +1 more source

In vitro models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of CRISPR perturbations

Molecular Oncology, EarlyView.
Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra, Shamsudheen Karuthedath Vellarikkal, Lixia Li, Hong Sun, Khoa Nguyen, Amber Montano, Suchitra Natarajan, Federica Piccioni, Alex Michael Tamburino, Xin Yu, Aleksandra Katarzyna Olow   +10 more
wiley   +1 more source

Evaluating Photochemical Interactions Between Rose Bengal Photodynamic Antimicrobial Therapy and Topical Antifungals in Fungal Keratitis Isolates. [PDF]

Invest Ophthalmol Vis Sci
Krishna K, Chou B, Gonzalez L, Durkee H, Paudyal S, Ahmed A, Echeverri Tribin F, C L B Ferreira B, Lai J, Aguilar MC, Arboleda A, Leblanc R, Flynn HW, Amescua G, Parel JM, Miller D.   +15 more
europepmc   +1 more source

Effect of chemotherapy on passenger mutations in metastatic colorectal cancer

Molecular Oncology, EarlyView.
Changes in passenger mutation load and predicted immunotherapy response after chemotherapy treatment. Tumor cells rich with passenger mutations have increased sensitivity to chemotherapy. Correlation of passenger mutations with neoantigen load suggests highly mutated clones promote a more effective response to immunotherapy, and therefore, first‐line ...
Marium T. Siddiqui, Matthew A. Cottam, Muhammad Bilal Mirza, Keeli B. Lewis, Kristen K. Ciombor, Mary Kay Washington, Kamran Idrees   +6 more
wiley   +1 more source

Matrix Metalloproteinases in Hepatocellular Carcinoma: Mechanistic Roles and Emerging Inhibitory Strategies for Therapeutic Intervention. [PDF]

Cancers (Basel)
Dimesa AM, Coban MA, Shoari A.
europepmc   +1 more source

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

New England Journal of Medicine, 2012
K. Flaherty, J. Infante, A. Daud, R. Gonzalez, R. Kefford, J. Sosman, O. Hamid, L. Schuchter, J. Cebon, N. Ibrahim, R. Kudchadkar, H. Burris, G. Falchook, A. Algazi, K. Lewis, G. Long, I. Puzanov, P. Lebowitz, A. Singh, S. Little, P. Sun, A. Allred, D. Ouellet, Kevin B. Kim, K. Patel, J. Weber   +25 more
semanticscholar   +1 more source